Floatz logo

xb010

Esophageal Squamous Cell Cancer

ExelixisPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

64 Active assets in the Esophageal Squamous Cell Cancer cohort.

Asset / SponsorPhaseRating
Eloxatin
Taiho Oncology, Inc.
Phase 3BB
FLUOROURACILUM
AstraZeneca
Phase 3BB
Irinotecan
Taiho Oncology, Inc.
Phase 2BB
Levoleucovorin
Taiho Oncology, Inc.
Phase 3BB
Cetuximab
Hummingbird Bioscience
Phase 2B

View all 50 →

Same molecule, other indications

xb010 is also rated in:

head and neck squamous cell carcinomaDormant
CC
Indicative ·
43 / 100
View asset →
hormone receptor-positive breast cancerDormant
CC
Indicative ·
43 / 100
View asset →
Locally Advanced or Metastatic Solid TumorsDormant
CC
Indicative ·
41 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →